Recce Pharmaceuticals Ltd
ASX:RCE
Recce Pharmaceuticals Ltd
ASX:RCE
Price:
0.46
AUD
-3.16%
Market Cap:
AU$133m
Add Note
Add Target
Capture your thoughts and set a target
Decide at what price you'd be comfortable buying and we'll help you stay ready.
Based on
Margin of Safety
0%
10%
20%
30%
40%
50%
Your Price Target
Linked to
current price
· In Buy Zone
Loading
Note attached
Choose the stock you wish to monitor with a price target
Recently Viewed
|
Recce Pharmaceuticals Ltd
ASX:RCE
|
AU |
|
L1 Group Ltd
F:PIJ0
|
AU |
|
EFORT Intelligent Equipment Co Ltd
SSE:688165
|
CN |
|
W
|
Worldex Industry & Trading Co Ltd
KOSDAQ:101160
|
KR |
|
EFG International AG
OTC:EFGIF
|
CH |
|
H
|
Haiphong Packing VICEM JSC
VN:BXH
|
VN |
|
S
|
Shanxi Blue Flame Holding Co Ltd
SZSE:000968
|
CN |
|
Global Capital Markets Ltd
BSE:530263
|
IN |
|
J
|
Jiangsu Favored Nanotechnology Co Ltd
SSE:688371
|
CN |
|
S
|
Sparebank 1 Ostlandet
OSE:SPOL
|
NO |
Multiples-Based Value
The Multiples-Based Value of one
RCE
stock under the Base Case scenario is
hidden
AUD.
Compared to the current market price of 0.46 AUD,
Recce Pharmaceuticals Ltd
is
hidden
.
Multiples-Based Value is the estimated value of a stock based on various valuation multiples like P/E and EV/EBIT ratios. It offers a quick snapshot of a stock's valuation in relation to its peers and historical norms.
Relative Valuation FAQ:
RCE Multiples-Based Value
LOCKED
Multiples Across Competitors
RCE Competitors Multiples
Recce Pharmaceuticals Ltd Competitors
Recce Pharmaceuticals Ltd Competitors
All Countries
| Market Cap | P/S | P/E | EV/EBITDA | EV/EBIT | ||||
|---|---|---|---|---|---|---|---|---|
| AU |
|
Recce Pharmaceuticals Ltd
ASX:RCE
|
137.4m AUD | 117.4 | -4.4 | -5.3 | -5.3 | |
| US |
|
Eli Lilly and Co
NYSE:LLY
|
829.8B USD | 12.9 | 40.6 | 27.4 | 29.3 | |
| US |
|
Johnson & Johnson
NYSE:JNJ
|
579B USD | 6.2 | 21.8 | 15.1 | 18.6 | |
| CH |
|
Roche Holding AG
SIX:ROG
|
248.4B CHF | 4 | 19.3 | 11.5 | 12.9 | |
| UK |
|
AstraZeneca PLC
LSE:AZN
|
228B GBP | 5.2 | 29.9 | 16.5 | 23.3 | |
| US |
|
Merck & Co Inc
NYSE:MRK
|
296B USD | 4.5 | 16 | 9.9 | 12.1 | |
| CH |
|
Novartis AG
SIX:NOVN
|
228.6B CHF | 5.3 | 21.2 | 13.1 | 16.9 | |
| IE |
E
|
Endo International PLC
LSE:0Y5F
|
237.1B USD | 102.3 | -81.1 | 375.3 | 941.3 | |
| DK |
|
Novo Nordisk A/S
CSE:NOVO B
|
1T DKK | 3.3 | 10 | 7.5 | 8.7 | |
| US |
|
Pfizer Inc
NYSE:PFE
|
153.7B USD | 2.5 | 20.3 | 7.8 | 10.4 | |
| US |
|
Bristol-Myers Squibb Co
NYSE:BMY
|
120.2B USD | 2.5 | 17.1 | 7.2 | 8.9 |
P/S Multiple
P/E Multiple
EV/EBITDA Multiple
EV/EBIT Multiple
